Fundsmith Reduces $19M in Doximity, Inc. ($DOCS)

Fundsmith slashed its holdings in Doximity, selling 958,216 shares.

Written by Trueearnings · Published Jun 14, 2026, 4:53 AM EDT

Key Points

Fundsmith reduced its stake in Doximity by 58%, selling 958,216 shares and leaving it with 691,786 shares valued at $13.86 million.
Doximity trades at $20.04 with a market cap of $3.66 billion, a P/E ratio of 20.45, and a 52-week range between $17.15 and $76.51.
Insider transactions included CEO Jeffrey Tangney selling 14,964 shares, and analysts have mixed ratings with targets ranging from $18 to $42.

Fundsmith has significantly reduced its holdings in Doximity, Inc. (NYSE:DOCS), according to its latest filing with the SEC dated May 15, 2026. The fund cut its position by 58%, selling 958,216 shares. This brings its total holdings to 691,786 shares, valued at approximately $13.86 million.

What Changed in Fundsmith's Doximity Position

Fundsmith's decision to cut back on its Doximity stake reflects a reduction from 1,650,002 shares to 691,786 shares, a decrease of 958,216 shares. This move represents a 58% reduction in its position, with the remaining shares valued at $13.86 million.

Other Institutional Activity in Doximity

In other institutional moves, BlackRock, Inc. trimmed its Doximity holdings by 103,666 shares, ending with 14,256,525 shares valued at $332.18 million. Vanguard Portfolio Management LLC acquired 6,394,107 shares, bringing its total to the same number, valued at $148.98 million. Vanguard Capital Management LLC also made a significant addition, acquiring 5,765,063 shares valued at $134.33 million. ClearBridge Investments, LLC reduced its stake by 91,443 shares, while William Blair Investment Management, LLC sold 622,765 shares, ending with 4,834,220 shares worth $112.64 million.

Doximity Stock Snapshot

Shares of Doximity, Inc. (NYSE:DOCS) are trading around $20.04. The company has a market capitalization of approximately $3.66 billion and a P/E ratio of 20.45. Its forward P/E is 12.55, and the stock has a beta of 1.293. Over the past year, Doximity's stock has ranged from a low of $17.15 to a high of $76.51. Its 50-day moving average is $22.44, and its 200-day moving average is $41.73.

Recent Earnings

Doximity reported revenue of $644.86 million, with a growth rate of 5.1%. The company's net margin stands at 30.4%, and it has a return on equity of 19.28%. The next earnings report is scheduled for August 6, 2026.

Insider Buying and Selling at Doximity, Inc.

On June 8, 2026, Sitaram Siddharth, Interim PAO, engaged in multiple transactions involving 5,000 shares each, both buying and selling. On May 15, 2026, CEO Jeffrey Tangney sold 14,964 shares at an average price of $18.01.

Analysts Set New Price Targets

On May 15, 2026, Barclays downgraded Doximity to a 'hold' with a $20 price target. On May 14, 2026, Jefferies also downgraded it to 'hold' with a $19 target. Meanwhile, Leerink Partners maintained a 'buy' rating with a $25 target, and Canaccord Genuity kept its 'buy' rating with a $30 target. The consensus recommendation is a 'buy' with a mean price target of $25.42 from 19 analysts.

About Doximity

Doximity, Inc. operates a digital platform tailored for medical professionals in the U.S. The company provides a personalized newsfeed of clinical and professional content, along with workflow tools such as a HIPAA-compliant AI assistant and telehealth solutions. Headquartered in San Francisco, California, Doximity serves a wide range of healthcare professionals and systems. The company is led by CEO Jeffrey A. Tangney and employs around 880 people.

Bottom Line

Fundsmith's substantial reduction in its Doximity holdings marks a significant shift in its investment strategy. Investors often track such filings to gauge fund managers' confidence in a company's future prospects. It's important to remember that 13F filings are historical and might not reflect the current position.